ATE317700T1 - Verwendung von (11beta, 17beta)-11-(1,3- benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)- estra-4,9-dien-3-on zur behandlung von schweren depressionen - Google Patents

Verwendung von (11beta, 17beta)-11-(1,3- benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)- estra-4,9-dien-3-on zur behandlung von schweren depressionen

Info

Publication number
ATE317700T1
ATE317700T1 AT02781273T AT02781273T ATE317700T1 AT E317700 T1 ATE317700 T1 AT E317700T1 AT 02781273 T AT02781273 T AT 02781273T AT 02781273 T AT02781273 T AT 02781273T AT E317700 T1 ATE317700 T1 AT E317700T1
Authority
AT
Austria
Prior art keywords
estra
benzodioxol
dien
hydroxy
treatment
Prior art date
Application number
AT02781273T
Other languages
English (en)
Inventor
Cornelis Sennef
Bernardus Wijnand M M Peeters
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE317700T1 publication Critical patent/ATE317700T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02781273T 2001-10-26 2002-10-21 Verwendung von (11beta, 17beta)-11-(1,3- benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)- estra-4,9-dien-3-on zur behandlung von schweren depressionen ATE317700T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01204072 2001-10-26

Publications (1)

Publication Number Publication Date
ATE317700T1 true ATE317700T1 (de) 2006-03-15

Family

ID=8181136

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06101005T ATE420649T1 (de) 2001-10-26 2002-10-21 Verwendung von (11beta, 17beta)-11-(1,3- benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)- estra-4,9-dien-3-on zur behandlung von schweren depressionen
AT02781273T ATE317700T1 (de) 2001-10-26 2002-10-21 Verwendung von (11beta, 17beta)-11-(1,3- benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)- estra-4,9-dien-3-on zur behandlung von schweren depressionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06101005T ATE420649T1 (de) 2001-10-26 2002-10-21 Verwendung von (11beta, 17beta)-11-(1,3- benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)- estra-4,9-dien-3-on zur behandlung von schweren depressionen

Country Status (26)

Country Link
US (1) US20040266863A1 (de)
EP (2) EP1652526B1 (de)
JP (1) JP4647909B2 (de)
KR (1) KR20050038580A (de)
CN (1) CN100531738C (de)
AT (2) ATE420649T1 (de)
AU (1) AU2002348996B2 (de)
BR (1) BR0213466A (de)
CA (1) CA2463446C (de)
CY (1) CY1110173T1 (de)
DE (2) DE60209248D1 (de)
DK (1) DK1652526T3 (de)
EC (1) ECSP045080A (de)
ES (1) ES2319563T3 (de)
HR (1) HRP20040370B1 (de)
HU (1) HUP0500070A3 (de)
IL (2) IL161248A0 (de)
IS (1) IS2702B (de)
MX (1) MXPA04003781A (de)
NO (1) NO332978B1 (de)
NZ (1) NZ532429A (de)
PL (1) PL206687B1 (de)
PT (1) PT1652526E (de)
RU (1) RU2302245C2 (de)
WO (1) WO2003037354A1 (de)
ZA (1) ZA200403088B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080061A1 (en) * 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
CA2585317C (en) * 2004-11-19 2015-02-24 N.V. Organon Drug combination for the treatment of depression and related disorders comprising a selective serotonin reuptake inhibitor
JP2009535430A (ja) * 2006-05-02 2009-10-01 コーセプト セラピューティクス, インコーポレイテッド Il−2を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターiiアンタゴニストの使用
US8658128B2 (en) * 2011-02-03 2014-02-25 Pop Test Cortisol Llc System and method for diagnosis and treatment
WO2012145258A1 (en) * 2011-04-18 2012-10-26 Pop Test Cortisol Llc Hair loss treatment
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
DE4447401A1 (de) * 1994-12-23 1996-07-04 Schering Ag 14,17-C¶2¶-überbrückte Steroide
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
DE19727772A1 (de) * 1997-06-30 1999-01-28 Forschungszentrum Juelich Gmbh Magnetflußsensor mit ringförmiger Sonde
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
JP2004525135A (ja) * 2001-03-23 2004-08-19 コーセプト セラピューティクス, インコーポレイテッド 糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法
ATE492281T1 (de) * 2001-05-04 2011-01-15 Corcept Therapeutics Inc Verwendung von glucocorticoid-rezeptor- spezifischen antagonisten zur behandlung von delirium
ATE411013T1 (de) * 2001-08-31 2008-10-15 Corcept Therapeutics Inc Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom

Also Published As

Publication number Publication date
ZA200403088B (en) 2005-01-24
HUP0500070A2 (hu) 2005-04-28
RU2004116082A (ru) 2005-05-10
IL161248A (en) 2010-12-30
EP1652526A2 (de) 2006-05-03
EP1441739B1 (de) 2006-02-15
DE60209248D1 (de) 2006-04-20
IL161248A0 (en) 2004-09-27
AU2002348996B2 (en) 2008-06-05
IS7204A (is) 2004-03-31
ECSP045080A (es) 2004-06-28
WO2003037354A1 (en) 2003-05-08
DK1652526T3 (da) 2009-05-18
KR20050038580A (ko) 2005-04-27
HRP20040370B1 (hr) 2012-09-30
JP4647909B2 (ja) 2011-03-09
NZ532429A (en) 2004-10-29
MXPA04003781A (es) 2004-07-30
CN1582153A (zh) 2005-02-16
HK1087357A1 (en) 2006-10-13
ATE420649T1 (de) 2009-01-15
ES2319563T3 (es) 2009-05-08
DE60230936D1 (de) 2009-03-05
EP1652526A3 (de) 2006-08-02
PL206687B1 (pl) 2010-09-30
PL369261A1 (en) 2005-04-18
EP1652526B1 (de) 2009-01-14
HRP20040370A2 (en) 2004-08-31
US20040266863A1 (en) 2004-12-30
HUP0500070A3 (en) 2012-09-28
JP2005521637A (ja) 2005-07-21
NO20041651L (no) 2004-04-23
RU2302245C2 (ru) 2007-07-10
CY1110173T1 (el) 2015-01-14
EP1441739A1 (de) 2004-08-04
CA2463446A1 (en) 2003-05-08
CA2463446C (en) 2010-02-23
PT1652526E (pt) 2009-02-06
NO332978B1 (no) 2013-02-11
CN100531738C (zh) 2009-08-26
IS2702B (is) 2010-11-15
BR0213466A (pt) 2004-11-09

Similar Documents

Publication Publication Date Title
UA83620C2 (ru) Замещенные бензоксазолы и их аналоги как эстрогенные агенты
BG104544A (en) Novel acylguanadine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
ATE252560T1 (de) Steroidrezeptor-modulator verbindungen und methoden
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
ES2124905T3 (es) Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad.
MXPA04005784A (es) 2-fenilbenzofuranos sustituidos como agentes estrogenitos.
CY1110173T1 (el) Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης
NO20020282D0 (no) Nytt difenylpiperidinderivat
DE60115274D1 (de) Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
BR0207066A (pt) Derivados do 2h-1-benzopirano - processos para sua preparação e composições farmacêuticas a partir deles
BG103060A (bg) 19- нор- холан стероиди като неврохимични инициатори на промяната в действието на хипоталамуса причовек
NO20014961L (no) Integrin-reseptor-ligander
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest
AR018313A1 (es) Kit anticonceptivo que comprende medios para la administracion diaria de un agente anticonceptivo, uso de un compuesto esteroide que tiene un perfil deactividad que combina inherentemente las actividades progestagenicas y estrogenicas y un metodo anticonceptivo
NO20022712L (no) Umettede 14,15-syklopropanandrostaner, fremgangsmåte for deres fremstilling, og farmasöytiske preparater som inneholderdisse forbindelsene
NO974256L (no) Anvendelse av anti-östrogener som befruktningshindrende midler for menn
DK1090028T3 (da) Umættede 14,15-cyclopropano-androstaner, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser
IL125983A0 (en) Pharmaceutical composition comprising factor xiiia